Kerry L. Spillane

Medicine · Health Sciences

4h-index255citations25works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(23), Protein Degradation and Inhibitors(23), Click Chemistry and Applications(8), RNA Interference and Gene Delivery(5), Histone Deacetylase Inhibitors Research(2)

Publications25 total

Cell line information from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supporting data Fig 4A from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supporting data Fig 3A, 3B, 4D, S6 from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figure legends from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary tables from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Data from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figures from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figures from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary Materials and Methods from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supporting data Fig 4A from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Data from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary Materials and Methods from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary tables from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Cell line information from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figure legends from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supporting data Fig 3A, 3B, 4D, S6 from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Blood·2021
Abstract B19: Targeting dependencies within apoptotic pathways through inhibition of BET bromodomains
Clinical Cancer Research·2017
Association of Gestational Weight Gain during Twin Gestations and Adverse Maternal Outcomes
Scholar Commons (University of South Carolina)·2017Open Access
Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300
Journal of Medicinal Chemistry·2016· 94 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Andrew R. Conery(23), Richard C. Centore(22), Barbara M. Bryant(22), Jennifer A. Mertz(22), Robert J. Sims(22), Archana Bommi‐Reddy(21), Charlie Hatton(19), Nicole E. Follmer(19), Patricia Greninger(18), Arnaud Amzallag(18), Cyril H. Benes(18), Eneida Pardo(4), Laura E. Zawadzke(4), Karen E. Gascoigne(4), Adrianne Neiss(3), Patricia J. Keller(3), Shivangi Joshi(3), Péter Sandy(3), Charlie Hatton(3), Terry D. Crawford(1)